Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

Exclusion criteria

• ✕. Within the first 2 weeks randomly selected, patients have received topical drug treatment for atopic dermatitis (AD), such as TCS, TCI, PDE inhibitors, Janus kinase (JAK) inhibitors, etc.
• ✕. Within the first 4 weeks before randomization, the patients received systemic treatment with traditional Chinese medicine (TCM) of unknown nature or with therapeutic effects on AD. Or within the first 1 week before randomization, they received topical treatment with Chinese herbal medicine of unknown nature or with therapeutic effects on AD.
• ✕. Received systemic glucocorticoids or other immunosuppressants/immunomodulators (including but not limited to cyclosporine, mycophenolate mofetil, interferon γ \[IFN-γ\], JAK inhibitors, compound glycyrrhizin, azathioprine, mycophenolate mofetil, and methotrexate) randomly within the first 4 weeks or 5 half - lives (whichever is longer).
• ✕. Received phototherapy (including but not limited to narrow - band ultraviolet B \[NBUVB\], ultraviolet B \[UVB\], ultraviolet A1 \[UVA1\], psoralen plus ultraviolet A \[PUVA\]), tanning beds, or any other light - emitting devices with therapeutic effects on atopic dermatitis (AD) within the first 4 weeks randomly.
• ✕. Randomly selected patients who had received allergen-specific immunotherapy (SIT) within the previous 6 months.
• ✕. Received any monoclonal antibody therapy (such as dupilumab, etc.) within the first 4 months randomly or within 5 half-lives (whichever is longer) before randomization; Received any cell - depleting agents, including but not limited to rituximab, within 6 months before randomization.
• ✕. As judged by the researchers, patients had no response or poor efficacy to previous treatment with anti-IL-4 and/or IL-13 drugs (such as dupilumab, etc.).
• ✕. Previously, 611 was used.